Navigation Links
Starpharma and Elanco Sign Agreement
Date:5/11/2009

MELBOURNE, Australia, May 11 /PRNewswire/ -- Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company.

The parties will collaborate to develop new animal health products with enhanced properties using Starpharma's dendrimer technology. Under the agreement, Starpharma will receive revenue from research fees, and is eligible for milestone payments and royalties on sale of any product developed. Elanco will receive exclusivity within the animal health field. Terms were not disclosed.

"We are very pleased to have secured such a strong animal health partner as Elanco for our delivery technology," said Dr Jackie Fairley, CEO, Starpharma.

"Their expertise, resources and market presence will be enormously valuable assets as we work to bring these innovative products to market," Fairley said. "An exciting aspect of this application for our business is that product development in the animal health sector can be faster than is usually associated with the development of human drugs."

The collaboration with Elanco is further demonstration of Starpharma's strong and successful partnership model and the multiple potential applications of its dendrimer technology. Starpharma also has partnerships with SSL International (Durex(R)), Siemens (Dade Behring), EMD Merck, Stiefel, Unilever, Qiagen and Sigma Aldrich.

Starpharma retains all rights to exploit the technology outside of Elanco's specific field of interest, including for all uses in humans, and continues to work to add to its portfolio of partners for drug delivery and dendrimer technology more widely.

In 2008, the global animal health market was reported to be about US$19 billion. Global sales are expected to reach US$21.7B by 2010, at which time the top three markets are forecast to be USA, China and Brazil, with the USA accounting for 40 percent of growth [1].

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

    For further information:

       Media
       Buchan Consulting
       Rebecca Wilson
       Tel: +61 3 9866 4722
       Mob: +61 417 382 391
       rwilson@bcg.com.au

       Ellie Papathanasiou
       Tel: +61 2 9237 2800
       epapathanasiou@bcg.com.au

       Starpharma
       www.starpharma.com
       Dr Jackie Fairley
       Chief Executive Officer
       +61 3 8532 2704

       Ben Rogers
       Company Secretary
       +61 3 8532 2702
       ben.rogers@starpharma.com

[1]Vetnosis for global animal health market estimate; all other information in "World Animal Health Markets" from Informa Healthcare, January 2008.


'/>"/>
SOURCE Starpharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
2. Heifer and Elanco Announce Charitable Partnership
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
5. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
6. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
9. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
10. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors on ... to help personal injury victims find high quality medical care. When the company started ... area. Fast forward to present day and the now ten-page directory features a vast ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: